Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity?

Lupus

Volumn 18, Issue 3, 2009, Pages 216-222

  De La Torre, Ma ^a   Urra, J M ^b   Blanco, J ^c  

^a HOSPITAL SAN AGUSTÍN   (Spain)

^b Hospital General   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

gp130; IL 6; Lupus monitoring; Nephritis; Renal lupus

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 60449113784     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308096068     Document Type: Article

References (34)

1. Herrmann M, Voll R, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000; 21: 424-426.
2. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 22-27.
3. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
4. Linker-Israeli M, Deans RD, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147: 117-123.
5. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.
6. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993; 151: 6525-6534.
7. Tesar V, Jirsa M, Masek Z, et al. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Cas Lek Cesk 1998; 137: 271-275.
8. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtando R, Avalos-Diaz E. Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 1998; 7: 154-158.
9. Horii Y, Iwano M, Hirata E, et al. Role of interleukin-6 in the progression of mesiangial proliferative glomerulonephritis. Kidney Int Suppl 1993; 39: S71-S75.
10. Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993; 4: 58-61.
11. Pelton BK, Hylton W, Denman AM. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 1992; 89: 251-254.
12. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
13. Hirano T. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998; 16: 249-284.
14. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp-130 is shared among the receptor for the interleukin-6 related cytokine subfamily. Stem Cells 1994; 12: 262-277.
15. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A. 2005; 102: 9589-9594.
16. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-1157.
17. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
19. Golbus J, McCune WJ. Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin North Am 1994; 20: 213-242.
20. De La Torre M, Alcazar R, Urra JM, et al. Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis. Transplant Proc 1998; 30: 3952-3954.
21. Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces expression of an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004; 16: 1621-1627.
22. Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332-1342.
23. Tesar V, Masek Z, Rychlik I, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998; 13: 1662-1667.
24. Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 2005; 64: 849-853.
25. O'Brien CA, Lin SC, Bellido T, Manolagas SC. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. J Cell Biochem 2000; 1479: 532-541.
26. Lin SCH, Yamate T, Taguchi Y, et al.Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest 1997; 100: 1980-1990.
27. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120-1126.
28. Memoli B, Grandaliano G, Soccio M, et al. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. J Am Soc Nephrol 2005; 16: 1099-1107.
29. Nossent JC, Swaak AJG, Berden JHM. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end stage renal failure treated with hemodialysis or continous ambulatory peritoneal dialysis. Am J Med 1990; 89: 169-174.
30. Asanuma Y, Chunq CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 445-447.
31. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: A model of the cytokine system. Citokine Growth Factor Rev 1997; 8: 241-252
32. Narimatsu M, Maeda H, Itoh S, et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol 2001; 21: 6615-6625.
33. Yellin MJ, Ulrich Thiene U. T cells in the pathogenesis of systemic lupus erythematosus: Potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000; 2: 24-31.
34. Bijl M, Horst G, Limburg P, Kallenberg C. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): Relation to lymphocyte activation and disease activity. Lupus 2001; 10: 866-872.